Estimate of anti-Plasmodium falciparum sporozoite activity in humans vaccinated with synthetic circumsporozoite protein (NANP)3
Jonathan R. Davis(University of Maryland, Baltimore), Myron Levine(University of Maryland, Baltimore), D A Herrington(University of Maryland, Baltimore), David F. Clyde(University of Maryland, Baltimore), James R. Murphy(University of Liverpool), Shahida Baqar(Naval Medical Research Command)
Transactions of the Royal Society of Tropical Medicine and Hygiene
November 1, 1989
Cited by 15
Related Papers
Genetic Epidemiology of COPD (COPDGene) Study Design
|COPD Journal of Chronic Obstructive Pulmonary Disease|2010|1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. I. Laboratory and Epidemiologic Observations
|Clinical Infectious Diseases|1983|754
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Variants in FAM13A are associated with chronic obstructive pulmonary disease
|Nature Genetics|2010|423